Clinical Research Directory
Browse clinical research sites, groups, and studies.
PK/PD of Ceftazidime Avitbatan Sodium in Children With Severe Infection
Sponsor: Children's Hospital of Fudan University
Summary
Ceftazidime avitbatan sodium is a broad-spectrum antibiotic with an antimicrobial spectrum covering resistant gram-negative bacteria. Its use in pediatric intensive care for severe infections is not unusual. Pathophysiological changes in severe sepsis can lead to significant changes in pharmacokinetics and pharmacodynamics during continuous renal replacement therapy.This research aims to study change of pharmacokinetic and pharmacodynamic in severe infection children with extracorporeal life support, thus improve the treatment of severe sepsis and sepsis shock.
Official title: Pharmacokinetics and Pharmacodynamics of Ceftazidime Avitbatan Sodium in Children With Severe Infection
Key Details
Gender
All
Age Range
3 Months - 18 Years
Study Type
OBSERVATIONAL
Enrollment
30
Start Date
2022-10-01
Completion Date
2026-12-31
Last Updated
2026-03-16
Healthy Volunteers
No
Conditions
Interventions
Ceftazidime Avitbatan Sodium
For 6-18 years children, 62.5 mg/kg/once，q8h ; 3-6 months of age 50 mg/kg/ once,q8h, intravenous administration for 2 hours, daily dose is not more than 2.5g, children will be administrated at least five times.
Locations (1)
Children's hosptial of fudan university
Shanghai, Shanghai Municipality, China